Issue 2, 2019

β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine

Abstract

We describe the preparation of a cancer vaccine candidate by conjugating a MUC1 peptide antigen to the β-glucan polysaccharide, which serves both as a carrier and an immune activator. In contrast to amorphous polysaccharides, peptide–β-glucan conjugates form uniform nanoparticles that facilitate the delivery of antigens and binding to myeloid cells, thus leading to the activation of both innate and adaptive immunity.

Graphical abstract: β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine

Supplementary files

Article information

Article type
Communication
Submitted
25 Sep 2018
Accepted
03 Dec 2018
First published
03 Dec 2018

Chem. Commun., 2019,55, 253-256

β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine

H. Wang, B. Yang, Y. Wang, F. Liu, A. Fernández-Tejada and S. Dong, Chem. Commun., 2019, 55, 253 DOI: 10.1039/C8CC07691J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements